Share this article
Share this article
ResearchAndMarkets.com s offering.
Major players in the trastuzumab biosimilar market are Amgen Inc., Pfizer Inc, Samsung Bioepis, Merck & Co., Biocon Limited, Mylan Inc., BioXpress Therapeutics, Celltrion, Teva Pharmaceutical Industries Ltd. and EirGenix, Inc.
The global trastuzumab biosimilars market is expected to decline from $1.27 billion in 2019 to $1.25 billion in 2020 at a compound annual growth rate (CAGR) of -1.50%.
The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $3.12 billion in 2023 at a CAGR of 35.50%.
Terry Gou to acquire stake in biotech firm
04/10/2021 06:52 PM
Terry Gou / CNA file photo
Taipei, April 10 (CNA) Terry Gou (郭台銘), the founder of Taiwan-based manufacturing giant Hon Hai Precision Industry Co., has agreed to acquire a stake in biosimilar drug developer EirGenix Inc. that will make him the company s largest shareholder.
Gou signed a memorandum of understanding with EirGenix Inc. earlier this week to acquire a 18.56 percent stake in the biotech company for NT$5.03 billion (US$177 million) through Hung Wei Co., which is owned by Gou.
According to EirGenix Inc., which is listed on Taiwan s over-the-counter market, it is launching a rights issue to sell 35 million new shares and a private placement to sell an additional 55 million new shares to raise funds.
Positive Phase III Clinical Results for EirGenix s Proposed Trastuzumab Biosimilar prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.